A Study of LY3484356 in Women With Breast Cancer Before Having Surgery

PHASE1CompletedINTERVENTIONAL
Enrollment

86

Participants

Timeline

Start Date

April 21, 2021

Primary Completion Date

November 11, 2022

Study Completion Date

November 11, 2022

Conditions
Breast Cancer
Interventions
DRUG

LY3484356

Administered orally.

Trial Locations (19)

1070

Institut Jules Bordet, Brussel - Capital

3000

Universitaire Ziekenhuizen Leuven - Campus Gasthuisberg, Leuven

19049

Helios Kliniken Schwerin, Schwerin

28007

Hospital General Universitario Gregorio Marañon, Madrid

28050

Hospital Madrid Norte Sanchinarro, Madrid

30322

Winship Cancer Center Emory University, Atlanta

37203

Sarah Cannon Research Institute SCRI, Nashville

60611

Northwestern Memorial Hosptial, Chicago

63110

Washington University School of Medicine, St Louis

77030

Baylor College of Medicine, Houston

University of Texas MD Anderson Cancer Center, Houston

80336

Klinikum der Universitaet Muenchen, München

91054

Universitätsklinikum Erlangen, Erlangen

92210

Hôpital René Huguenin, Saint-Cloud

02114

Massachusetts General Hospital, Boston

05401

University of Vermont Medical Center, Burlington

08036

Hospital Clinic I Provincial, Barcelona

TR1 3LJ

The Royal Cornwall Hospital, Truro

EC1A 7BE

Barts Cancer Institute, London

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY